کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2124237 | 1547248 | 2008 | 5 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer? When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?](/preview/png/2124237.png)
چکیده انگلیسی
Until the publication of two pivotal trials, there were no treatment options available that did prolong the overall survival in men with hormone refractory prostate cancer (HRPC). Currently, docetaxel-based cytotoxic treatment is considered as a standard of care in all the patients with progressive metastatic HRPC. The use of this treatment regimen renders an equal survival benefit in all the subgroups of patients; however, there is a substantial difference in the overall survival between the subgroups. This review addresses the optimal timing of the cytotoxic treatment in asymptomatic patients with HRPC.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Journal of Cancer - Volume 44, Issue 9, June 2008, Pages 1193-1197
Journal: European Journal of Cancer - Volume 44, Issue 9, June 2008, Pages 1193-1197
نویسندگان
P. Hamberg, P.C.M.S. Verhagen, R. de Wit,